In re Baycol Products Litigation

219 F.R.D. 468, 2003 WL 23096021
District Court, D. Minnesota·Decided December 12, 2003·No. No. MDL 1431 (MJD/JGL)·Published·Cited by 5 cases

Opinion

PRETRIAL ORDER NO. 98

DAVIS, District Judge.

This matter is before the Court upon Defendants’ Motion to Conduct Informal Ex Parte Interviews of Plaintiffs’ Treating Physicians. The Parties have filed briefs, and the Court heard oral argument on this issue at the November 3, 2003 Status Conference.

I. BACKGROUND

This motion arises in the context of a multi-district litigation (“MDL”) involving alleged injuries suffered as a result of taking the prescription drug Baycol. Baycol was prescribed to lower the lipid levels of individuals with high cholesterol. In August 2001, Baycol was removed from the market after thirty-one deaths in the United States were linked to Baycol use. Plaintiffs in this MDL were either prescribed Baycol or represent the interests of individuals who were prescribed Baycol. Plaintiffs have all signed releases, giving Defendants access to their medical records. However, Defendants argue that in order to provide a “level playing field” (Nov. 3, 2003 Status Conf. Tr. at 25), they also need to conduct ex parte interviews of Plaintiffs’ physicians. Specifically, Defendants assert that if Plaintiffs have unfettered access to their physicians prior to formal depositions, Plaintiffs will have the unfair advantage of “presenting] their view of the case to the treating physicians, potentially unjustifiably biasing them against defendants in advance of deposition, all without the fear of directly disclosing their mental impressions and case strategy.” (Def. Mem. Supp. Mot. at 8.) Defendants aver that Plaintiffs have waived the physician-patient privilege, and therefore Plaintiffs’ physicians are merely ordinary fact witnesses whom Defendants should be allowed to interview. In the alternative, Defendants seek to. amend PTO 96 to allow discovery depositions of Plaintiffs’ physicians prior to conducting trial depositions.

II. DISCUSSION

A. Legal Standard

There is no physician-patient privilege in federal diversity actions. See Filz v. Mayo Found., 136 F.R.D. 165, 167 (D.Minn.1991) (citations omitted). Therefore, for federal cases based on diversity jurisdiction, state law controls the existence and scope of the physician-patient privilege. See id.; Lind v. Canada Dry Corp., 283 F.Supp. 861, 865 (D.Minn.1968) (addressing the scope of waiver of physician-patient privilege). Under Minnesota law, physician-patient privilege is governed by Minn.Stat. § 595.02 which states, in pertinent part:

[Subd.] 1.
[470]*470(d) A licensed physician or surgeon ... shall not, without consent of the patient, be allowed to disclose any information or any opinion based thereon which the professional acquired in attending the patient in a professional capacity, and which was necessary to enable the professional to act in that capacity.
* * * * * *
Subd. 5.
A party who commences an action for malpractice, error, mistake, failure to cure, whether based on contract or tort, against a health care provider ... waives in that action any privilege existing ... as to any information or opinion in the possession of a health care provider who has examined or cared for the party or other person whose health or medical condition has been placed in controversy in the action. This waiver must permit all parties to the action, and their attorneys or authorized representatives, to informally discuss the information or opinion with the health care provider if the provider consents. Prior to an informal discussion with a health care provider, the defendant must mail written notice to the other party at least 15 days before the discussion. The plaintiffs attorney or authorized representative must have the opportunity to be present at the informal discussion.

Minn.Stat. § 595.02 subd. 1(d), 5.

When a party places his or her medical condition at issue, the physician-patient privilege is waived to the extent provided by Minn. R. Civ. P. 35.03, and limited by Minn. R. Civ. P. 35.04. Rule 35.04 provides that medical records must be produced, but does not mention ex parte interviews of treating physicians. In addition, Rule 35.04 states that depositions of treating physicians are only allowed upon court order for good cause shown.

B. The Parameters of State Privilege Law

The Court finds that, on its face, the scope of Minnesota privilege law does not allow the ex parte communications Defendants desire. Minn.Stat. § 595.02 is clear: without Plaintiffs’ consent, their treating physicians may not disclose any information. Since Plaintiffs have put their medical conditions in controversy, Plaintiffs have executed waivers in which they allow Defendants access their medical records, nothing more. These waivers comport with Rule 35.04. Defendants argue that “there can be no claim that the physician/patient privilege has not been waived. Thus, plaintiffs’ physicians should be treated as any other fact witnesses, and defendants should have the right to interview willing physicians.” (Def. Mem. Supp. Mot. at 7.) The Court finds this argument misplaced. The truth is that “there can be no claim that the physician-patient privilege has not been waived only to the extent outlined, in Minn. R. Civ. P. 35.04.” Plaintiffs executed limited waivers which comport with state law. See Younggren v. Younggren, 556 N.W.2d 228, 233 (Minn.Ct.App.1996) (stating that a waiver pursuant to Rule 35.04 only allows opposing party access to medical records). Plaintiffs were not required to do any more than that and, under the facts of this case, the Court does not find that justice requires that Plaintiffs execute more expansive waivers.

In Wenninger v. Muesing, 307 Minn. 405, 240 N.W.2d 333 (1976), the Minnesota Supreme Court stated that Minnesota’s limited physician-patient privilege waiver rules exist for the following reasons:

The policy underlying Rule 35.03 is the full disclosure of all relevant medical evidence concerning plaintiffs health when he voluntarily puts his health in issue by bringing a lawsuit.... The procedure defined in Rule 35.04 protects both the patient and his physician from the danger that adverse counsel may abuse his opportunity to interrogate the physician by privately inquiring into facts or opinions about the patient’s mental and physical health or history which may neither be relevant to the patient’s lawsuit nor lead to the discovery of admissible evidence. In a formal deposition pursuant to Rule 35.04, the presence of a patient’s counsel ... assure[s] that clearly irrelevant medi[471]*471cal testimony will not be elicited. Private, nonadversary interview's of the doctor by adverse counsel would offer no such protection to the patient’s right of privacy. The presence of the patient’s counsel at the doctor’s interrogation permits the patient to know what his doctor’s testimony is, allays a patient’s fears that his doctor may be disclosing personal confidences, and thus helps preserve the complete trust between doctor and patient which is essential to the successful treatment of the patient’s condition.

Free access — add to your briefcase to read the full text and ask questions with AI

In re Baycol Products Litigation, 219 F.R.D. 468, 2003 WL 23096021 (mnd 2003).

219 F.R.D. 468 (In re Baycol Products Litigation) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Kutz v. NGI Capital, Inc.
D. Minnesota, 2023
Kraft v. Essentia Health
D. North Dakota, 2022
Laabs v. Nor-Son, Inc.
D. Minnesota, 2021
In re American Medical Systems, Inc.
946 F. Supp. 2d 512 (S.D. West Virginia, 2013)